Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 71

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 71
---

involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

We have agreed to indemnify the
Selling Securityholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the
registration of the shares offered by this prospectus.

We have agreed with the Selling
Securityholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such
time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement
or (2) the date on which all of the shares may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 of the Securities
Act and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144.

Company Offering

Pursuant to an engagement
agreement, dated as of July 16, 2025, we have engaged Maxim Group LLC, or the placement agent, to act as our exclusive placement agent
to solicit offers to purchase the securities offered in the Company Offering pursuant to this prospectus on a reasonable best-efforts
basis. The engagement agreement does not give rise to any commitment by the placement agent to purchase any of our securities, and the
placement agent will have no authority to bind us by virtue of the engagement agreement. The placement agent is not purchasing or selling
any of the securities offered by us under this prospectus, nor is it required to arrange for the purchase or sale of any specific number
or dollar amount of securities. The placement agent does not guarantee that it will be able to raise new capital in any prospective offering.
This offering will terminate within one year of the effective date, unless we decide to terminate the offering (which we may do at any
time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public
offering price per share of common stock (or pre-funded warrant) and accompanying warrant, in the Company Offering, will be fixed for
the duration of this offering.

We will enter into a securities
purchase agreement directly with certain institutional investors, at such investor’s option, which purchase our securities in this
offering. Investors that do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the
purchase of our securities in this offering. There is no minimum number of securities or amount of proceeds that is a condition to closing